TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study

(2015) A. Gunther et al.   HAEMATOLOGICA

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study

(2015) A. Gunther et al.   HAEMATOLOGICA

Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib

(2014) Ilyas Sahin et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

(2014) Andrew J. Yee et al.   BRITISH JOURNAL OF HAEMATOLOGY

SEOM clinical guidelines for the treatment of renal cell carcinoma

(2014) J. Bellmunt et al.   Clinical & Translational Oncology

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

(2014) Jason R. Westin   Clinical Lymphoma Myeloma & Leukemia

Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring aPIK3CAMutation

(2014) Rishi Agarwal et al.   Journal of Breast Cancer

Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.

(2014) J. R. Infante et al.   MOLECULAR CANCER THERAPEUTICS

Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma

(2014) D. Cirstea et al.   MOLECULAR CANCER THERAPEUTICS

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K

(2014) Daniel J. Ma et al.   NEURO-ONCOLOGY

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

(2013) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Metabolic complications with the use of mTOR inhibitors for cancer therapy

(2013) Shanthi Sivendran et al.   CANCER TREATMENT REVIEWS

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

(2013) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models

(2012) Yesim Gökmen-Polar et al.   BREAST CANCER RESEARCH AND TREATMENT

605 A Phase 1, Open-label, Dose-escalation Study of Oral Administration of the Investigational Agent MLN0128 in Combination with Paclitaxel (P) in Patients (pts) with Advanced Solid Malignancies

(2012) H. Burris et al.   EUROPEAN JOURNAL OF CANCER

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

(2012) Naifa L. Busaidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

(2012) M R Janes et al.   LEUKEMIA

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

Defining the role of TORC1/2 in multiple myeloma

(2011) P. Maiso et al.   BLOOD

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

(2011) Arkaitz Carracedo et al.   CELL CYCLE

mTOR signaling in disease

(2011) Eva Dazert et al.   CURRENT OPINION IN CELL BIOLOGY

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

(2011) Irene M Ghobrial et al.   LANCET ONCOLOGY

Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors

(2011) E. Vilar et al.   MOLECULAR CANCER THERAPEUTICS

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Utility of mTOR Inhibition in Hematologic Malignancies

(2011) A. Younes et al.   ONCOLOGIST

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

(2010) B. Hoang et al.   BLOOD

Target of Rapamycin Signaling in Leukemia and Lymphoma

(2010) C. Vu et al.   CLINICAL CANCER RESEARCH

Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

(2010) T E Witzig et al.   LEUKEMIA

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Dissecting the role of mTOR: Lessons from mTOR inhibitors

(2009) Ryan J.O. Dowling et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia

(2008) Meletios Athanasios Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY